<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html>
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
        <meta name="format-detection" content="telephone=no"> 
        <meta name="viewport" content="width=device-width; initial-scale=1.0; maximum-scale=1.0; user-scalable=no;">
        <meta http-equiv="X-UA-Compatible" content="IE=9; IE=8; IE=7; IE=EDGE" />
        <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-1BmE4kWBq78iYhFldvKuhfTAU6auU8tT94WrHftjDbrCEXSU1oBoqyl2QvZ6jIW3" crossorigin="anonymous">
        <link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.15.4/css/all.css" integrity="sha384-DyZ88mC6Up2uqS4h/KRgHuoeGwBcD4Ng9SiP4dIRy0EXTlnuz47vAwmeGwVChigm" crossorigin="anonymous"/>
        <title>HTML EMAIL</title>
        
        <style type="text/css">
            @media only screen and (min-width: 960px) {
                /* styles for browsers larger than 960px; */
            }
            @media only screen and (min-width: 1440px) {
                /* styles for browsers larger than 1440px; */
            }
            @media only screen and (min-width: 2000px) {
                /* for sumo sized (mac) screens */
            }
            @media only screen and (max-device-width: 480px) {
                 /* styles for mobile browsers smaller than 480px; (iPhone) */
            }
            @media only screen and (device-width: 768px) {
                /* default iPad screens */
            }
                /* different techniques for iPad screening */
            @media only screen and (min-device-width: 481px) and (max-device-width: 1024px) and (orientation:portrait) {
                /* For portrait layouts only */
            }

            @media only screen and (min-device-width: 481px) and (max-device-width: 1024px) and (orientation:landscape) {
                /* For landscape layouts only */
            }
        </style>

        <link rel="stylesheet" href="style.css">

    </head>
    <body>
        <div class="container">
            <div> 
                <div class="col-one">
                    <p><b>From: </b>DiscoverTIL@iovance.com<p>
                    <p><b>Subject line:</b></p>
                    <p>Discover the science of tumor infiltrating lymphocytes (TIL) at DiscoverTIL.com</p>
                    <p>ALT: Find out about the science of tumor infiltrating lymphocytes (TIL) in multiple solid tumors</p> 
                    <p>ALT: Explore how tumor infiltrating lymphocytes (TIL) work naturally in the body</p>
                </div>
                
                <br>
                
                <div class="col-two">
                    <img src="images/EmailDesign_03.png" alt="discoverPic">
                </div>

                <br>

                <div class="col-three">
                    <p>Tumor infiltrating lymphocytes (TIL) are part of the body’s
                        natural response to cancer. For patients who have not
                        responded to or who have progressed on immune
                        checkpoint inhibitors,TIL are being investigated as a
                        potential treatment option in multiple solid tumors.<sup>1-3</sup><p>
                </div>
                <div class="col-four">
                    <img src="images/EmailDesign_07.jpg" alt="learnPic">
                </div>

                <br>

                <div class="col-five">
                    <p>IOVANCE Biotherapeutics is committed to deepening the
                        understanding of TIL and optimizing TIL technology to help
                        shape the next chapter of TIL cell therapy.</p>
                </div>

                <br>

                <div class="col-six">
                    <img src="images/EmailDesign_10.jpg" alt="learnPic">
                </div>

                <br>
                
                <div class="col-seven">
                    <footer>
                        <p> <b>References: 1.</b> Rosenberg SA, Spiess P,      Lafreniere R. A new approach to the adoptive
                        immunotherapy of cancer with tumor-infiltrating lymphocytes. Science.
                        1986;233:1318-1321. <b>2.</b> Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint
                        inhibitors: recent progress and potential biomarkers.Exp Mol Med. 2018;50(12):165.
                        <b> 3. </b> Nowicki TS, Hu-Lieskovan S, Ribas A.Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J.2018;24(1):47-53.</p>   
                    </footer>
                </div>

                
                <div class="col-eight">
                    <div class="logo"><img src="images/EmailDesign_13.png" alt="Logo"></div>
                    <div class="contactText">
                    <p> 
                        CONTACT US | PRIVACY POLICY | UNSUBSCRIBE 
                    </p>
                    <p> 
                        Iovance Biotherapeutics <br> 
                        999 Skyway Rd <br>
                        Suite 150 <br>
                        San Carlos, CA 94070
                    </p>
                    <p>
                        © 2020 IOVANCE Biotherapeutics, Inc. All Rights Reserved.
                        <br>
                        IOVANCE logo is a trademark owned by Iovance
                        <br>
                        Biotherapeutics, Inc.
                        <br>
                        PRC-US-00032(v1.0)
                    </p>
                    </div>

                    <br>
                    <br>
                    

                </div>
                <hr style="width:100%;color:#0d176b">
            </div>
        </div>
    </body>
</html>     